Oral Tau Aggregation Inhibitor for Alzheimer’s Disease : Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

Wischik, Claude M.Bentham, P.Gauthier, S.Miller, S.Kook, K.Schelter, B. O.2022-10-052022-10-052022-10Wischik, C M, Bentham, P, Gauthier, S, Miller, S, Kook, K & Schelter, B O 2022, 'Oral Tau Aggregation Inhibitor for Alzheimer’s Disease : Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate', Journal of Prevention of Alzheimer's Disease, vol. 9, pp. 780-790. https://doi.org/10.14283/jpad.2022.632274-5807https://hdl.handle.net/2164/19291Acknowledgements: We gratefully acknowledge the contribution of the scientific advisory board, study investigators, and the generosity of study participants. The authors thank EVERSANA™ for providing medical writing support, which was funded by TauRx Therapeutics in accordance with Good Publication Practice (GPP3) guidelines ( http://www.ismpp.org/gpp3 ). Funding: The study was funded and sponsored by TauRx Therapeutics (Singapore). The funder of the study took the lead in designing and conducting the study, as well as writing of the report.111196799engSubstantive connection via an eligible employment contractSDG 3 - Good Health and Well-beingAlzheimer’s diseasehydromethylthionine mesylateLeuco-methylthioninium bis(hydromethanesulphonate)LMTMtau aggregation inhibitorR Medicine (General)Clinical NeurologyPsychiatry and Mental healthR1Oral Tau Aggregation Inhibitor for Alzheimer’s Disease : Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine MesylateJournal article10.14283/jpad.2022.63http://www.scopus.com/inward/record.url?scp=85132707248&partnerID=8YFLogxK9